Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China Authorizes New Inactivated Vaccine Amid Doubt Over Sinopharm Jabs

Efficacy In New Spotlight In Seychelles

Executive Summary

A new emergency authorization marks China’s fourth approval for inactivated COVID-19 vaccines, despite lingering doubts over the protection offered by the technology and surging cases in one of the most vaccinated countries where Sinopharm’s inactivated vaccines are widely used.

You may also be interested in...



Breakthrough COVID-19 Cases Raise Concern Over B.1.617 Variant

As the B.1.617 variant of SARS-CoV-2 spreads to countries including the UK and US after having caused havoc in India, vaccine effectiveness against this variant is under the lens with breakthrough cases reported post full vaccination. Meanwhile, CEPI’s offer to help in testing against variants has potential to harmonize assessment of COVID-19 vaccines performance.

CanSino's Inhaled COVID Vaccine Shows Early Promise As Potential Booster

Early study results show CanSino’s inhaled vaccine for COVID-19 triggered an immune response similar to its injected counterpart.

LinkDoc’s US Listing In Jeopardy Following China's New Data Security Requirements

The US listing of Chinese artificial intelligence, medical records and patient management system company Linkdoc could be derailed, after China issued new data review requirements tightening the oversight of overseas listings of domestic companies.

Topics

Related Companies

UsernamePublicRestriction

Register

SC144377

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel